Cancer Research · global
A new lead after breast cancer treatment resistance: Randomized samuraciclib trial supports CDK7 inhibition strategy
In a 59-patient trial, samuraciclib combined with endocrine therapy showed higher rates of disease control; the signal was stronger in patients with no detected TP53 mutations, but the small sample size and gastrointestinal side effects remain questions that the next stage of research must address.
When breast cancer progresses again after treatment with a CDK4/6 inhibitor, maintaining disease control is a challenge for patients and physicians. A randomized phase 2 trial published in *Nature Communications* on October 5 provides clinical evidence for another target, CDK7: the oral drug samuraciclib combined with fulvestrant produced numerically better disease control measures than fulvestrant alone, but the study was not large enough to establish an efficacy advantage.
The study, called SUMIT-BC, analyzed 59 women with hormone receptor-positive, HER2-negative advanced breast cancer who had previously received a CDK4/6 inhibitor. They received either 360 mg or 240 mg of samuraciclib daily plus fulvestrant, or fulvestrant alone, with 20, 19, and 20 patients in the three groups, respectively. Samuraciclib is intended to disrupt the gene transcription activity that sustains tumor growth; combining it with fulvestrant, which promotes estrogen receptor degradation, aims to inhibit cancer cells through different mechanisms.
The trial's primary endpoint, the clinical benefit rate, was 60.0%, 63.2%, and 40.0% in the 360 mg combination group, the 240 mg combination group, and the monotherapy group, respectively. This measure includes complete tumor disappearance, partial shrinkage, and stable disease lasting at least 24 weeks, so it cannot be interpreted directly as tumor shrinkage in six out of ten patients. Overall median progression-free survival was 7.8, 8.5, and 5.6 months, respectively; it measures the time without disease progression and does not equate to longer overall survival.
A more pronounced signal came from patients with no TP53 mutations detected in their blood before treatment. In this subgroup, median progression-free survival was 14.5 months with the 360 mg combination and 6.8 months with monotherapy. TP53 status was a prespecified analysis in the study, but these two groups contained only 13 and 11 patients; the absence of a detected mutation in blood also cannot guarantee that the tumor has no mutations at all. This finding supports further research using biomarkers to select patients, but it cannot yet establish a clinical rule for choosing treatment.
These results were previously presented at the San Antonio Breast Cancer Symposium in December 2025. Carrick Therapeutics' announcement at the time reported the same efficacy data for the 360 mg group, and its public resources page also includes the SUMIT-BC results poster by Sonia Pernas and colleagues. The peer-reviewed paper now provides a more complete public record of the randomized comparison, the two doses, and the study's limitations; it is the formal publication of the same trial, rather than a further validation of efficacy in another group of patients.
Beyond the disease control signal, the treatment burden was also substantial. Treatment-related diarrhea, nausea, and vomiting were common in the samuraciclib groups; diarrhea occurred in 80.0% of the 360 mg group and 52.6% of the 240 mg group. The study managed these adverse reactions with preventive measures and symptom management, but approximately four in ten patients in each combination group required dose reductions because of treatment-related adverse reactions. Whether the higher dose justifies more side effects still needs to be weighed in subsequent research.
Designed and funded by Carrick Therapeutics, the trial was open-label, with imaging-based efficacy assessments conducted by investigators and no blinded independent central review; the authors also explicitly stated that the sample size was insufficient for formal testing of statistical significance. The key next step is to confirm, in larger trials with more rigorous assessments, whether TP53 testing can identify patients who truly benefit, and to determine a dose that balances disease control and tolerability. The available data provide a reason to continue exploring CDK7 inhibition, but further evidence is still needed before it can change the standard of care.